REPLIMUNE GROUP INC. - COMMON STOCK

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

06 يونيو 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

03 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 مايو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update

16 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

07 أبريل 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

26 مارس 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Replimune to Present at the American Association for Cancer Research Annual Meeting 2024

06 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Replimune to Present at Three Upcoming Investor Conferences

05 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

08 فبراير 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

28 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

05 ديسمبر 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

08 نوفمبر 2023 08:10:00 بحسب Nasdaq GlobeNewswire

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

07 نوفمبر 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

03 نوفمبر 2023 18:30:00 بحسب Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 سبتمبر 2023 15:01:00 بحسب Nasdaq GlobeNewswire

Replimune Announces Appointment of Emily Hill as Chief Financial Officer

19 سبتمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

03 أغسطس 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

01 أغسطس 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Replimune Announces Sander Slootweg will Depart from its Board of Directors

20 يوليو 2023 07:00:01 بحسب Nasdaq GlobeNewswire